• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Johnson & Johnson Innovation in Canadian collaboration

Johnson & Johnson Innovation in Canadian collaboration

December 11, 2013
CenterWatch Staff

Johnson & Johnson Innovation is collaborating with two Canadian early-stage drug technology development centers to identify and advance biopharmaceutical technologies: Montreal-based NEOMED, a nonprofit, public-private pharma alliance dedicated to drug discovery and development; and Toronto-based MaRS Innovation, the commercialization agent for Ontario’s discovery pipeline from 16 academic institutions,

NEOMED is partially funded by the Ministère des Finances et de l’Économie du Québec, within the NEOMED Institute, a state-of-the-art R&D facility in the Montréal Technoparc. MaRS Innovation is supported by the government of Canada through the Networks of Centers of Excellence, by the Government of Ontario through the Ontario Centers of Excellence and by its 16 member institutions.

Technical experts from the Johnson & Johnson Innovation Center in Boston, Mass., will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies.

“We know from our history of engagement that the Canadian biopharmaceutical environment is one of the most vibrant in the world,” said Robert Urban, head of the Johnson & Johnson Innovation Center, Boston. “These new collaborations will allow us to potentially advance important new clinical candidates against disease.”

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing